Welcome to our dedicated page for Timber Pharmaceuticals news (Ticker: TMBR), a resource for investors and traders seeking the latest updates and insights on Timber Pharmaceuticals stock.
Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is a clinical-stage biopharmaceutical company advancing novel therapies for rare dermatologic conditions. This dedicated news hub provides investors with essential updates on corporate developments, clinical research milestones, and regulatory progress for lead candidate TMB-001.
Key resources include: Timely updates on the pending acquisition by LEO Pharma, progress reports from the Phase 3 ASCEND study, and strategic developments in the company's Chapter 11 reorganization process. All content is curated to help stakeholders track value-driving events including FDA communications and partnership announcements.
Regular updates cover: Clinical trial results for congenital ichthyosis treatments • Corporate restructuring developments • Strategic partnership updates • Regulatory filings and expert analysis of material events. Content is sourced from official SEC filings, press releases, and verified corporate communications.
Bookmark this page for consolidated access to TMBR's latest news. For historical documents and investor resources, visit Timber Pharmaceuticals' official website.
Timber Pharmaceuticals announced significant progress with its lead asset, TMB-001, which has received orphan drug designation from the European Commission for two severe types of congenital ichthyosis (ARCI and XLRI). The company has achieved 50% enrollment in its Phase 3 ASCEND clinical trial, launched in June 2022, following positive FDA interactions earlier in the year. Timber also secured Breakthrough Therapy and Fast Track designations for TMB-001. Financial results showed revenues of $83,177 for 2022, a decrease from $886,532 in 2021, with approximately $9.1 million in cash at year-end. The company is exploring partnerships to fund ongoing operations.
Timber Pharmaceuticals (TMBR) has announced positive results from a sub-analysis of its Phase 2b CONTROL study of TMB-001, a topical isotretinoin for treating congenital ichthyosis (CI).
The study found significant improvements among participants with both autosomal recessive congenital ichthyosis (ARCI) and X-linked recessive ichthyosis (XLRI) in achieving primary and secondary endpoints. In the intent-to-treat population, 33% to 100% of participants with ARCI and XLRI showed a 50% reduction in Visual Index for Ichthyosis Severity (VIIS) compared to vehicle treatments.
Results support continued development of TMB-001, which has orphan designation in Europe, as a promising alternative to systemic therapies.
FAQ
What is the market cap of Timber Pharmaceuticals (TMBR)?
